Article

Sue Friedman on Informed Decision-Making in Hereditary Breast and Ovarian Cancers

Author(s):

Sue Friedman

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network and the importance of informed decision-making.

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network, which is the first-ever patient-powered research registry created and governed by and for people affected by hereditary breast and ovarian cancers. In this clip, Friedman also stresses the importance of informed decision-making.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content
Illustration of Laura.
April 29th 2025

A Fellow Cancer Survivor Gives Me a Useful Message

Laura Yeager
A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
INX-315 received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer: © stock.adobe.com.
April 29th 2025

FDA Fast Tracks INX-315 for Tough-to-Treat Ovarian Cancer

Spencer Feldman
INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
The first patient has been dosed in a phase 1/2 trial investigating treatment with AP402, a T-cell engager, for patients with HER2-positive cancers: stock.adobe.com.
April 23rd 2025

First Patient Dosed with AP402 in a Trial for HER2 Advanced Tumors

Spencer Feldman
The combination of Enhertu plus Perjeta showed improvement in progression-free survival versus standard treatment among patients with HER2-positive metastatic breast cancer.
April 21st 2025

Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer

Ryan Scott
Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.